Aurinia Pharmaceuticals Inc. (AUPH) stock

AUPHNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 13/3062% below fair value

$15.73−0.48 (-2.96%)

Close on Nov 13, 2026Market cap $2.11BP/E 6.9Yield –

Aurinia Pharmaceuticals EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

Aurinia Pharmaceuticals's EV/EBITDA was 11.6× on Nov 11, 2026, against 22.9× a year earlier.

Period	Period end	Value	Change (pts)
2026	Nov 11, 2026	11.6×	−11.1
2025	Dec 31, 2025	22.7×	–

Parsed from the XBRL in Aurinia Pharmaceuticals's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is AUPH.

Revenue growth21.0% · median 38.4%

Gross margin90.6% · median 90.2%

Operating margin48.6% · median 6.9%

Net margin97.7% · median -1.8%

Advertisement
300 × 250

See a number that looks wrong?